AU Patent

AU2015203659A1 — Antisense nucleic acid

Assigned to Nippon Shinyaku Co Ltd · Expires 2015-07-23 · 11y expired

What this patent protects

The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin …

USPTO Abstract

The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015203659A1
Jurisdiction
AU
Classification
—
Expires
2015-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Nippon Shinyaku Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.